World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Big Drug R&D on Campus
Keywords:
Tags:
A new arrangement is being tried by pharmaceutical companies like Merck and Pfizer to develop new drugs. This is to have scientists inside major research universities and company scientists work together in searching for new drugs and working through the drug development process in a longer term collaboration arrangement, with scientists in universities learning how to work in a company environment and scientists in companies learning how to work in a university environment. On April 25, 2008 Pfizer invested $14 million in an alliance with 4 universities to study obesity and diabetes. Merck and Harvard are working on drug discovery for cancer, and just signed an agrement to develop treatments for bone disease osteoporosis. Efforts at collaboration would need to address issues like patent disputes, academic publication rights, cultural adjustment for university scientists who now have to work at getting FDA approval through a rigorous process. Policies are being developed to overcome the patent and publication issues and Harvard has hired 40 scientists from large pharmaceutical companies to coach university scientists on drug development.
Novartis is developing a whole new system for developing pharmaceutical treatments by putting medical science at the centre of things.
12/11/2007
Novartis' CEO Vasella, and Dr Fishman who heads the global research labs in Cambridge, Massachusetts, are redoing the way the company develops drugs and runs the company. Senior leaders are now medically trained scientists, and Novartis has shed much of the old marketing and sales staff. Drug discovery focusses on Dr. Fishman's approach to go after common molecular pathways and develop medicines for diseases that may be rare, but reveal the knowledge behind addressing all diseases that have that common underlying molecular pathway as the source of the diseases functioning.
Grouped Articles
Novartis Chairman Stresses Need for R&D Investment
Wall Street Journal 03/22/2014
Wall Street Journal 12/11/2007
Wall Street Journal 12/17/2007
BusinessWeek 05/08/2008
CEO Gambles on a Novartis Makeover
Wall Street Journal 05/20/2008
BusinessWeek 09/04/2008
Merck research and development
12/11/2007
Grouped Articles
Merck R&D Job Cuts Strip Layer of Senior Management
Wall Street Journal 06/15/2013
Merck Plans Radical Overhaul of Drug R&D Unit
Wall Street Journal 12/28/2013
Merck to Continue Development Of Cholesterol, Obesity Drugs
Wall Street Journal 12/11/2007
BusinessWeek 05/08/2008
Merck to Develop Biotech Generics
Wall Street Journal 12/10/2008
Wall Street Journal 11/18/2010
Pfizer research and development (R&D)
11/25/2006
Grouped Articles
Pfizer Outlines Post-Wyeth R&D Structure
Wall Street Journal 04/08/2009
Pfizer Tries to Sell Research Spending - WSJ.com
Wall Street Journal 11/25/2006
Weak Sales Prompt Pfizer to Cancel Diabetes Drug
New York Times 10/19/2007
As Drug Industry Struggles, Chemists Face Layoff Wave
Wall Street Journal 12/11/2007
BusinessWeek 05/08/2008
Pfizer Sets Pact for Alzheimer's Drug
Wall Street Journal 09/04/2008
Glaxo research and development.
03/27/2006
R&D at Glaxo SmithKline
Grouped Articles
Bureaucracy Buster? Glaxo Lets Scientists Choose Its New Drugs
Wall Street Journal 03/27/2006
BusinessWeek 05/08/2008
Glaxo Is Eliminating R&D Jobs As Part of Cost-Cutting Plan
Wall Street Journal 06/12/2008
Glaxo Aims to Cut R&D Staff by 6%
Wall Street Journal 09/30/2008
Wall Street Journal 05/26/2010
Glaxo Tries Biotech Model to Spur Drug Innovations
Wall Street Journal 07/01/2010
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us